Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?

American Journal of Ophthalmology

Volumn 145, Issue 3, 2008, Pages

  Chen, Aiyin ^a   Prajna, Lalitha ^b   Srinivasan, Muthiah ^d   Mahalakshmi, Rajendran ^b   Whitcher, John P ^a,c   McLeod, Stephen ^a,c   Lietman, Thomas M ^a,c   Acharya, Nisha R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ARAVIND EYE HOSPITAL   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PLACEBO; PREDNISOLONE 21 PHOSPHATE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL KERATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CORNEA EPITHELIUM; DRUG RESPONSE; EPSILOMETER TEST; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INDIA; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE LINEAR REGRESSION ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCAR; VISUAL ACUITY;

EID: 39149135531     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.11.004     Document Type: Article

References (14)

1. Erie J.C., Nevitt M.P., Hodge D.O., and Ballard D.J. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol 111 (1993) 1665-1671
2. Gonzales C.A., Srinivasan M., Whitcher J.P., and Smolin G. Incidence of corneal ulceration in Madurai district, South India. Ophthalmic Epidemiology 3 (1996) 159-166
3. Whitcher J.P., and Srinivasan M. Corneal ulceration in the developing world: a silent epidemic. Br J Ophthalmol 81 (1997) 622-623
4. Wilhelmus K.R. Review of clinical experience with microbial keratitis associated with contact lenses. CLAO J 13 (1987) 211-214
5. Greenwood D. In vitro veritas?. Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 144 (1981) 380-385
6. Lorian V., and Burns L. Predictive value of susceptibility tests for the outcome of antibacterial therapy. J Antimicrob Chemother 25 (1990) 175-181
7. Stroman D.W., Dajcs J.J., Cupp G.A., and Schlech B.A. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 50 (2005) S16-S31
8. Schlech B.A., and Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (Vigamox). Surv Ophthalmol 50 (2005) S7-S15
9. Brown D.F.J., and Brown L. Evaluation of the Etest, a novel method of quantifying antimicrobial activity. J Antimicrob Chemother 27 (1991) 185-190
10. Baker C.N., Stocker S.A., Culver D.H., and Thornsberry C. Comparison of the Etest to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 29 (1991) 533-538
11. Seventeenth International Supplement, CLSI M-100-S17. Performance standards for antimicrobial susceptibility testing (2006), Clinical Laboratory Standards Institute, Wayne, Pennsylvania 44-49 64-65
12. Barron B.A., Gee L., Hauck W.W., et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 101 (1994) 1871-1882
13. McLeod S.D., LaBree L.D., Tayyanipour R., Flowers C.W., Lee P.P., and McDonnell P.J. The importance of initial management in the treatment of severe infectious corneal ulcers. Ophthalmology 102 (1995) 1943-1948
14. Wilhelmus K.R., Abshire R.L., and Schlech B.A. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 121 (2003) 1229-1233